Zymeworks Inc products

Zymeworks’ lead product candidate, zanidatamab, is a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric platform. Zanidatamab is currently being evaluated in global Phase 1, Phase 2 and pivotal clinical trials as a best-in-class treatment for patients with HER2-expressing cancers, including biliary tract, gastroesophageal adenocarcinomas, breast, and other tumor types.

ZW49 is a HER2-targeted antibody drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ platforms. ZW49 is currently being evaluated in a Phase 1 clinical trial as a treatment for patients with locally advanced or metastatic HER2-expressing cancers that have progressed following treatment with existing approved therapies, including HER2-targeted agents. ZW49 combines the unique design of zanidatamab with a proprietary cytotoxin and cleavable linker. ZW49 delivers a novel auristatin (cell-killing compound) to tumor cells by taking advantage of the enhanced antibody-HER2 internalization of zanidatamab.  

using precise antibody Fc modifications that tailor the antibody-mediated immune response. Get the optimal response. Tailor immune system response for a desired therapeutic effect using the Effector Function Enhancement and Control Technology’s (EFECT™) library of Fc region modifications. The EFECT™ library includes proprietary mutations to the CH2 domain of the antibody`s Fc region to selectively modulate an antibody’s interactions with the Fc-gamma receptors (FcgR) expressed on the surface of immune cells and with a component of the complement pathway (i.e. C1q).

in a single, transferable, conditionally active design. Right Place at the Right Time. With PROgrammed Tumor Engagement & Checkpoint/Co-stimulation Targeting, the ProTECT platform delivers multifunctional tumor-specific activity while simultaneously enhancing immune modulation through the conditional activity of a natural immunomodulatory pair such as PD-1/PD-L1. Therapeutics utilizing ProTECT™ have limited exposure and activity in normal healthy tissue, avoiding on-target, off-tumor toxicities. Once in the tumor microenvironment, proteases cleave and release one half of the functional block. This activates both the targeting antibody and the immunomodulatory function when and where it is needed.

by creating tailored multifunctional therapeutics that enable enhanced efficacy and new biological approaches for treating diseases. Two is better than one. Create novel mechanisms of action through unique binding. Azymetric™ is the best-in-class platform for therapeutic antibodies that can simultaneously bind to multiple distinct locations on a target or to multiple targets, resulting in unique mechanisms of action not accessible through typical monospecific antibodies. Azymetric™ bispecific antibodies can block multiple signaling pathways, recruit immune cells to tumors, enhance receptor clustering and internalization, and increase tumor-specific targeting.